Research Insights
Research Insights section focuses on the cutting-edge and breakthrough research that is happening all over the world. Laboratories across the globe are working hard to develop drugs and therapies for various diseases and research insights directly from them add tremendous value.
Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis
Abstract Rationale Tuberculosis remains a worldwide problem particularly with the advent of multidrug resistance Shortening therapy duration for Mycobacterium tuberculosis is a major goal requiring generation of optimal kill rate and resistancesuppression Combination therapy is required to attain the goal of shorter therapy Objectives Our objec...
Methods for Specifying the Target Difference in a Randomised Controlled Trial: The Difference ELicitation in TriAls (DELTA) Systematic Review
Abstract Background Randomised controlled trials RCTs are widely accepted as the preferred study design for evaluating healthcare interventions When the sample size is determined a target difference is typically specified that the RCT is designed to detect This provides reassurance that the study w
Recent Mitochondrial DNA Mutations Increase the Risk of Developing Common Late-Onset Human Diseases
Abstract Mitochondrial DNA mtDNA is highly polymorphic at the population level and specific mtDNA variants affect mitochondrial function With emerging evidence that mitochondrial mechanisms are central to common human diseases it is plausible that mtDNA variants contribute to the missing heritability of several complex traits Given the cent
Adverse Effects and Regimen Switch among Patients on Antiretroviral Treatment in a Resource Limited Setting in Ethiopia
Abstract Background Highly active antiretroviral therapy is the cornerstone of management of patients with human immunodeficiency virus infection Antiretroviral therapy can prolong survival of patients however this drugs are associated with adverse effects that can affect patient adherence and if severe may require regimen change The aim of the stu...
Statistical Designs for Assessing Interchangeability of Biosimilar Products
More and more biopharmaceutical andor biotech companies begin to concern regulatory approval of biosimilar products due to some innovator products will expire in decades Once more biological products are going off patient the problem whether approving biosimilar products used interchangeably and safely will be considered Using a biological product...
RNAi Therapeutic Platforms for Lung Diseases
Yu Fujita Fumitaka Takeshita Kazuyoshi Kuwano and Takahiro Ochiya Division of Molecular and Cellular Medicine National Cancer Center Research Institute Tokyo Japan Division of Respiratory Diseases Department of Internal Medicine Jikei University School of Medicine Tokyo Japan
Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
Department of Clinical Pharmacy University of California San Francisco San Francisco California United States of America Department of Epidemiology and Biostatistics University of California San Francisco San Francisco California United States of America Division of General Internal Medicine University of California San Francisco San Francisco C...
Factors Associated with Findings of Published Trials of Drug-Drug Comparisons: Why Some Statins Appear More Efficacious than Others
Kristian Pietras Jessica Pahler Gabriele Bergers Douglas Hanahan Department of Biochemistry and Biophysics Diabetes Center and Comprehensive Cancer Center University of California San Francisco San Francisco California United States of America Ludwig Institute for Cancer Research Karolinska Institutet Sto
Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
Ansar A Pathan Clare R Sander Helen A Fletcher Ian Poulton Nicola C Alder Natalie E R Beveridge Kathryn T WhelanAdrian V S Hill Helen McShane Centre for Clinical Vaccinology and Tropical Medicine University of Oxford Churchill Hospita
Factors Associated with Findings of Published Trials of Drug-Drug Comparisons: Why Some Statins Appear More Efficacious than Others
Lisa Bero Fieke Oostvogel Peter Bacchetti Kirby Lee Clinical Pharmacy and Health Policy University of California San Francisco California United States of America Department of Mathematics University of Leiden The Netherlands Department of Epidemiology and Biost
